Advancing Discoveries in Fibrosis

Posters

• PLN-74809, A dual-selective inhibitor of integrins αvβ6 and αvβ1 shows dose-dependent target engagement in the lungs of patients with idiopathic pulmonary fibrosis (IPF)
  
• PLN-74809, an oral, dual-selective αvβ6/αvβ1 inhibitor in phase 2 clinical trials for idiopathic pulmonary fibrosis (IPF), sustainably reduces transforming growth factor-beta (TGF-β) activity in the lungs of healthy participants with once-daily dosing
  
• PLN-74809, a dual-selective inhibitor of αvβ6 and αvβ1, is well tolerated in over 280 healthy participants
  
• Therapeutic biomarker discovery in idiopathic pulmonary fibrosis (IPF) through proteomic analysis of precision-cut lung slice (PCLS) supernatants
  
• Pharmacological inhibitors of integrin αvβ6 that differentially modulate protein conformation are similarly effective at inhibiting TGF- β signaling in the fibrotic lung
  
• Profiling fibrosis regression in a rat model of non-alcoholic steatohepatitis
  
• PK/PD assessment of an oral, selective αVβ6 /αVβ1 integrin dual antagonist, PLN-74809, for the treatment of idiopathic pulmonary fibrosis
  
• Dual αVβ6 /αVβ1 inhibitor PLN-74809 blocks multiple TGF-β activation pathways associated with IPF
  
• PLN-74809, a dual αVβ6/αVβ1 integrin inhibitor, inhibits fibrosis in precision-cut liver tissue from PSC and PBC patients and the Mdr2 knockout mouse
  
• PLN-74809, a dual αvβ6/αvβ1, oral, selective integrin inhibitor, is well tolerated and reduces lung TGF-β activity in healthy volunteers
  
• Selective Small Molecule Inhibitor of Integrin αvβ8 and αvβ1 Has Single Agent Activity and Potentiates Immune Checkpoint Blockade Therapy